Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. Brueckmann
Pdb63 - Cost-Effectiveness Analysis of Empagliflozin Treatment in Patients With Type 2 Diabetes and Chronic Heart Failure Based on Subgroup of Empa-Reg Outcome in the United Kingdom
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Pdb62 - Cost-Effectiveness Analysis of Empagliflozin in Japan Based on Results From the Subgroup Analysis of Asian Patients in the Empa-Reg Outcome Trial
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost of Type 2 Diabetes Management and Associated Complications in the United Kingdom
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pdb71 - Assessing the Relative Cost-Effectiveness of Empagliflozin and Canagliflozin for the Treatment of Type 2 Diabetes Patients With Existing Cardiovascular Disease in the Uk
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness of Insulin Degludec Compared With Insulin Glargine for Patients With Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pdb76 - Cost-Effectiveness Analysis of Empagliflozin in Comparison to Liraglutide Based on Cardiovascular Outcome Trials
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Trends in Cause-Specific Outcomes Among Individuals With Type 2 Diabetes and Heart Failure in the United Kingdom, 1998-2017
JAMA network open
Medicine
A Statistical Analysis of the Treatment of Type 2 Diabetes in the Presence of Chronic Kidney Disease in Patients Hospitalized for Heart Failure
Studies in Systems, Decision and Control
Control
Systems Engineering
Finance
Automotive Engineering
Decision Sciences
Economics
Econometrics
Optimization
Computer Science
Social Sciences
Ce1 - Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Consistent Cardiovascular (CV) Benefit of Empagliflozin Over the Spectrum of CV Risk Factor Control in EMPA-REG OUTCOME
Metabolism: Clinical and Experimental
Endocrinology
Metabolism
Diabetes
